Niacin 500 mg

Niacin 500 mg

Solaray4.6 (3,856 ratings)
Format:Capsule Quantity: 100 VegCap(s) · 100 servings
Goals
$12.29 $0.12 per serving
VitacostLowest$12.29iHerb$12.29Pure Formulas$12.29

About this product

A high niacin amount could directly affect lipid metabolism if the capsule contains nicotinic acid. The single-active design is easy to understand apart from that crucial missing identity.

The label does not specify the form, so flushing and cardiovascular usefulness cannot be confirmed. No controlled-release feature or tolerance guidance is supplied.

It fits only people who verify the form and use the amount with appropriate medical monitoring. It offers little targeted value for skin structure, hydration, or antioxidant coverage.

Who is it for
  • Clinician-guided users considering lipid-active niacin
  • Adults who can confirm the chemical form
  • People seeking a single-ingredient capsule
Best for
  • Potential lipid-marker support if form-confirmed
  • Focused vitamin B3 use
  • Supervised high-dose supplementation

Pros

  • Substantial active amount
  • Single-ingredient formula
  • Capsule format

Cons

  • Exact niacin form is missing
  • No release technology is stated
  • Only moderate practical value

Warnings

  • If this is nicotinic acid, the serving may cause marked flushing, itching, or dizziness
  • Sustained high-dose use may affect the liver, glucose, and uric acid
  • Lipid-directed use should be supervised rather than self-managed

Product analysis

76 out of 100
A high-dose niacin capsule with possible lipid relevance but insufficient form disclosure; confirm the ingredient and use only with suitable monitoring.

AI assessment of the formula, label and price. How scoring works

Nutrient quality68

Vitamin B3 is supplied at a meaningful amount in a simple formula. The unidentified form limits assessment of absorption, flushing risk, and suitability for the intended use.

Ingredient transparency80

Most stated amounts and the serving size are clear without a conventional proprietary blend. Form ambiguity, overlapping entries, or missing non-active ingredients leave important label gaps.

Customer satisfaction72

The average rating is strong, with a very large review count supporting the signal. No detailed reviews are supplied to assess repeated complaints or intended-use experiences.

Value for money83

The single-active formula and long supply provide fair value. The unidentified form and aggressive amount make cheaper label simplicity less meaningful.

Format
Capsule
Container
100 VegCap(s)
Per serving
$0.12
Also available
Niacin 100 mgB3 100 mg • 100 VegCap(s) • 100 servings$7.41
Customer rating
4.6 · 3,856 ratings
Report analysis

Goals

Heart Health
Heart Health
Impact
High effect
A- Goal FitB- Strength of SupportC CoverageA Formula Quality

High-dose niacin can directly affect lipid metabolism and is clearly relevant to cardiovascular risk management. The disclosed amount is within the range used for lipid-focused effects.

The exact niacin form is missing, so the likely lipid effect and flushing profile cannot be confirmed. The serving can cause flushing and may affect liver enzymes or glucose with sustained use, making medical monitoring important.

How this product is rated for Heart Health

Goal Alignment & Evidence Quality85

High-dose niacin is directly relevant to lipid metabolism and cardiovascular risk management. Human evidence supports nicotinic acid for lipid changes, though outcome benefits and tolerability require careful clinical use.

Effective Goal Contribution73

The disclosed niacin amount is substantial enough for lipid-focused effects. The label does not identify nicotinic acid, niacinamide, or a release format.

Pathway Coverage60

The single active targets lipid metabolism but not vascular tone, cardiac energy, or calcium handling. A substantial single-active serving provides strong depth in its chosen pathway.

Formulation Coherence94

The focused niacin formula has a clear lipid-management rationale. The single-active label avoids unrelated nutrients and redundant lipid ingredients.
Study evidence
Niacin Supportive 105 studies
Cardiovascular Support
Cardiovascular Support
Impact
High effect
A- Goal FitB- Strength of SupportC- CoverageA- Formula Quality
Niacin · 500 mg

High-dose niacin can directly alter blood lipids when supplied as nicotinic acid. Nicotinic acid has strong human evidence for lipid changes, although modern cardiovascular use requires individualized medical oversight.

The 500 mg amount is substantial enough for a pharmacologic lipid effect if the form is nicotinic acid. The label says niacin without confirming nicotinic acid, so cardiovascular effectiveness cannot be established from the form. A 500 mg niacin dose can cause flushing and may affect the liver, blood sugar, or uric acid, so lipid-focused use needs clinician oversight.

How this product is rated for Cardiovascular Support

Goal Alignment & Evidence Quality88

High-dose niacin can directly alter blood lipids when supplied as nicotinic acid. Nicotinic acid has strong human evidence for lipid changes, although modern cardiovascular use requires individualized medical oversight.

Effective Goal Contribution72

The 500 mg amount is substantial enough for a pharmacologic lipid effect if the form is nicotinic acid. The label says niacin without confirming nicotinic acid, so cardiovascular effectiveness cannot be established from the form.

Pathway Coverage55

The single active targets lipid management and does not cover blood pressure, rhythm, or endothelial support. A substantial dose could provide strong depth, but only if the undisclosed form is appropriate.

Formulation Coherence89

A focused niacin capsule has a clear lipid-management rationale. The single-active formula avoids unnecessary additions and duplication.
Study evidence
Niacin Supportive 136 studies

Ingredients

IngredientAmount per servingScore
Niacin
500 mg 35
Adults 18–50
Report overview
Niacin · 500 mg OverallScore35
F Active Ingredient Quality & BioavailabilityF Dose, Safety & Label TransparencyF Value
Niacin 500 mg lists an amount of niacin and includes a flushing warning, but it doesn't identify the form. Its cardiovascular focus is therefore hard to connect to a form-specific use, and the appropriate dose context is unclear. The cost is moderate for standard niacin.
How this ingredient is rated

Active Ingredient Quality & Bioavailability36

The saved details state a cardiovascular focus, but only say niacin; its specific form and source aren't identified.
Niacin Form & Goal Alignment
The product points to cardiovascular support, but doesn't say whether its niacin is nicotinic acid or another form.
Precursor Source Quality
The saved details do not identify a niacin source or advanced precursor.

Dose, Safety & Label Transparency37

The amount and a flushing warning are recorded, but the chemical form is not. That leaves the form-specific dose and warning context unclear.
Clarity of Chemical Form
The label lists niacin but does not name its chemical form.
Form-Specific Dosage Efficacy
The dose is stated, but its form is unknown, so it cannot be compared with a form-specific range.
Flush Risk & Safety Labeling
A flushing warning is recorded, but the form isn't identified, so its specific context is unclear.

Value30

The per-serving cost is moderate for standard niacin, though the form is unspecified.
Price Per Effective Serving
For the standard-niacin range, the recorded cost falls between the low and high price bands.
View ingredientView products
Loading alternative details
82 Performance

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best

Sustained-release nicotinic acid provides a clearly identified cardiovascular-focused amount with controlled delivery. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, high-dose niacin can still affect the liver and requires explicit safety guidance.

80 Performance

Niacin (Vitamin B3) 500 mg

Solgar

Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.

79 Performance

Niacin-Time 500 mg

Carlson

Timed-release nicotinic acid provides a transparent cardiovascular-focused dose in a long-supply format. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, controlled delivery does not remove flushing or liver-related concerns from high-dose niacin.

86 Budget

Niacinamide B-3 100 mg

Source Naturals

A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.

82 Budget

Niacin 100 mg

Nature's Way

Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. Serving cost is lower than the original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.

82 Budget

Niacin 100 mg

Bluebonnet

Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. Serving cost is lower than the original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.

80 Value

Niacin 50 mg

Carlson

A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its lower serving cost and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.

85 Value

Niacin 100 mg

Source Naturals

A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its lower serving cost and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.

80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar

Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  8. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  9. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  10. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  11. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  12. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  13. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  14. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  15. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  16. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  17. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin